Published on the 30th June 2014 by ANSTO Staff
Treating cancer patients with drugs requires a fine balance between killing tumour cells without damaging normal cells, and managing the body’s clearance of anti-cancer drugs so as to be effective without being toxic to the patient.
If the body clears chemotherapy drugs too quickly, the tumour attacking action is lost, while slower metabolism of anti-cancer drugs results in higher concentrations of these drugs in the body which in turn causes toxicity and forces treatment to be delayed or stopped. A better understanding of how to achieve this fine balance will help in the treatment of cancer patients. ANSTO’s Arvind Parmar and his colleagues have used the radiopharmaceutical technetium (99mTc) sestamibi, which acts as a marker, to investigate drug clearance and toxicity. Cancer-free and cancer bearing mice were studied using various medical imaging techniques to follow the distribution of the markers and better understand the underlying mechanisms in cancer treatment. The new understanding of how to use medical imaging to monitor clearance of chemotherapy medication, gained through this study, can now be applied in future studies aimed at Identifying patients at risk of toxicity. This will ultimately lead to better tailoring of medication doses for individual patients, which will make cancer treatment safer and more effective.
The challenges of chemotherapyWhen treating cancer patients with drugs, it is crucial to maintain a fine balance between killing tumour cells without damaging normal cells and managing the body’s clearance of anti-cancer drugs. Anti-tumour action is lost if the drug is cleared too rapidly, while slower metabolism of chemotherapy drugs results in higher concentrations in the body which, in turn, causes toxicity resulting in the delay or termination of treatment. One factor known to contribute to altered drug clearance in cancer patients is inflammation associated with the growth of tumours. We have previously found that the presence of a tumour causes a reduction in the enzymes and drug transporters in the liver that take up drugs from the bloodstream into organs such as liver, brain and bone marrow as well as pumping toxins out of the body. This reduction results in slower clearance of drugs. Because of this some patients develop adverse side effects from chemotherapy [1].
How can molecular imaging help?To assess the impact of tumour-derived inflammation on the activity of one family of drug transporters throughout the body, the bio-distribution of the radiopharmaceutical markers 99mTcsestamibi in cancer bearing and noncancer bearing mice was investigated. The radioisotope Technetium, 99mTc, is combined with a pharmaceutical agent to create a marker for nuclear imaging. For the imaging we used the new Inveon Tri-modality small-animal imaging system located at the Brain and Mind Research Institute (BMRI), an imaging facility run jointly with ANSTO. The imaging system is versatile as it can combine three techniques Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET) and Computed Tomography (CT) in a single integrated scanner (see Table 1 for details). This provides three-dimensional imaging of multiple dynamic volumes and that are required for our measurements of bio-distributions. In our studies, we tested the ability of 99mTc-sestamibi to act as a predictive marker for drug clearance and toxicity in normal tissues. Our results will clarify the mechanism linking cancer induced inflammation to reduced drug clearance and provide options for future clinical trials in cancer patients.
Imaging the biodistributionAnalysis of the imaging data shows that Colon 26 (C26) tumour-bearing mice have slower rates of clearance of 99mTc-sestamibi in kidneys, intestines, gall bladder and liver compared to the control mice (Figs.1&2) This finding was supported by ex-vivo tissue biodistribution data using a gamma counter which reduced accumulation was evident in intestines, liver, urine and bile fluid in the tumour groups compared to the controls (Fig.3). The significant differences in 99mTcsestamibi biodistribution and clearance indicate changes in the activity of transport proteins. As these drug transporters make a major contribution to clearance of many anti-cancer agents this study demonstrates the potential to use SPECT imaging with 99mTc-sestamibi for predicting drug clearance and toxicity in humans.
The Future
We are in the initial stages of understanding how to monitor the clearance of chemotherapeutic drugs based on these results. The differences in drug biodistribution and pharmacokinetics for tumour-bearing versus control mice are significant and lay the foundations for subsequent experiments aimed at reversing inflammatory signalling associated with cancer in mice.
We now plan to perform imaging with first line anti-cancer drugs as a prelude to clinical studies in human cancer patients to identify those at risk of excessive toxicity. We aim to characterise the functional impact of tumour-induced inflammation on anti-cancer drug pharmacokinetics and identify strategies to normalise drug handling, leading to improved individualisation of anti-cancer drug dosing, and hence safer and more effective chemotherapy for patients.
Progressively, we hope to establish diagnostic biomarkers to identify patients at greater risk of toxicity from chemotherapy prior to its use, enabling better surveillance and more appropriate use of prophylactic antibiotics and growth factors. The new knowledge generated from these studies has the potential to fundamentally change cancer chemotherapy dosing strategies to improve the safety and efficacy of cancer treatment.
This study is a component of NHMRC project grant ID#632848 –”Improving the use of chemotherapy” 2010-2012.
References
|
